CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The aim of this exploratory study is to assess the performance and tolerability of the MOBIDERM Intimate Bra in the management of breast ede ...
Paris, Paris 14, France
adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...
Phase 2
Saint-Cloud, France and 72 other locations
non-metastatic early-stage triple-negative (TNBC) or HER2+ breast cancer. TNBC cohort is composed of 2 open-label, randomized arms,...
Phase 2
Villejuif, France
Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherap...
Phase 3
Villejuif, France
This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have...
Phase 2
Paris, France and 10 other locations
participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast...
Phase 1, Phase 2
Paris, France and 22 other locations
-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this stud...
Phase 3
Villejuif, France and 52 other locations
This is a phase II study, preceded by a safety run-in, with two independent cohorts (cohort A in early Triple Negative Breast Cancer...
Phase 2
Paris, France and 1 other location
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer:A phase Ib/II, open-label, modular, dos ...
Phase 1, Phase 2
Villejuif, France
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Paris, France and 117 other locations
Clinical trials
Research sites
Resources
Legal